• Je něco špatně v tomto záznamu ?

Secretoneurin levels are higher in dilated cardiomyopathy than in ischaemic cardiomyopathy: preliminary results

J. Plášek, J. Dodulík, M. Lazárová, D. Stejskal, Z. Švagera, N. Chobolová, P. Šulc, L. Evin, D. Purová, J. Václavík

. 2023 ; 10 (-) : 1297900. [pub] 20240108

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006054

BACKGROUND: Secretoneurin (SN) is a neuropeptide with potential utility as a biomarker of cardiovascular episodes. The main effect of SN is mediated through its inhibition of calmodulin-dependent kinase II (CaMKII), which influences calcium handling. We aimed to associate the levels of SN in plasma with different causes of heart failure. METHODS: We prospectively enrolled consecutive patients with ischaemic (ICM) and dilated (DCM) cardiomyopathy from the outpatient heart failure clinic and healthy individuals. SN was analysed from venous blood by use of the ELISA method. SN plasma levels were compared in DCM, ICM and healthy individuals with non-parametric tests. RESULTS: A total of 53 patients (81.1% male, 18.9% female; mean age 67.9 ± 12.6 years) and 34 healthy individuals (38% male, 62% female) were included in the analysis. Plasma SN levels were significantly higher in the dilated cardiomyopathy (38.8 ± 27 pmol/L) as compared with the ischaemic cardiomyopathy (19.7 ± 22.6 pmol/L) group (P = 0.006). There was no significant difference between females vs. males (27.1 ± 23 vs. 25.5 ± 26.2 pmol/L, P = NS). Plasma SN levels allowed DCM and ICM to be differentiated with 88% sensitivity and 61% specificity (P = 0.007), the cut of value is 13.3 pmol/L. Plasma SN levels differed significantly between healthy volunteers and both ICM (P < 0.0001) and DCM (P = 0.049). Plasma SN levels did not differ according to age and were not associated with comorbidities, left ventricular ejection fraction, heart failure medication, troponin, creatinine, or natriuretic peptide plasma levels. CONCLUSION: Plasma secretoneurin levels differed significantly in DCM vs. ICM, being higher in the former. Based on plasma SN levels, discrimination between DCM and ICM might be possible. Healthy individuals produce higher SN plasma levels than stable HFrEF patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006054
003      
CZ-PrNML
005      
20250108155140.0
007      
ta
008      
240405e20240108sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fcvm.2023.1297900 $2 doi
035    __
$a (PubMed)38259301
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Plášek, Jiří $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czechia $u Research Center for Internal and Cardiovascular Diseases Faculty of Medicine, University of Ostrava, Ostrava, Czechia
245    10
$a Secretoneurin levels are higher in dilated cardiomyopathy than in ischaemic cardiomyopathy: preliminary results / $c J. Plášek, J. Dodulík, M. Lazárová, D. Stejskal, Z. Švagera, N. Chobolová, P. Šulc, L. Evin, D. Purová, J. Václavík
520    9_
$a BACKGROUND: Secretoneurin (SN) is a neuropeptide with potential utility as a biomarker of cardiovascular episodes. The main effect of SN is mediated through its inhibition of calmodulin-dependent kinase II (CaMKII), which influences calcium handling. We aimed to associate the levels of SN in plasma with different causes of heart failure. METHODS: We prospectively enrolled consecutive patients with ischaemic (ICM) and dilated (DCM) cardiomyopathy from the outpatient heart failure clinic and healthy individuals. SN was analysed from venous blood by use of the ELISA method. SN plasma levels were compared in DCM, ICM and healthy individuals with non-parametric tests. RESULTS: A total of 53 patients (81.1% male, 18.9% female; mean age 67.9 ± 12.6 years) and 34 healthy individuals (38% male, 62% female) were included in the analysis. Plasma SN levels were significantly higher in the dilated cardiomyopathy (38.8 ± 27 pmol/L) as compared with the ischaemic cardiomyopathy (19.7 ± 22.6 pmol/L) group (P = 0.006). There was no significant difference between females vs. males (27.1 ± 23 vs. 25.5 ± 26.2 pmol/L, P = NS). Plasma SN levels allowed DCM and ICM to be differentiated with 88% sensitivity and 61% specificity (P = 0.007), the cut of value is 13.3 pmol/L. Plasma SN levels differed significantly between healthy volunteers and both ICM (P < 0.0001) and DCM (P = 0.049). Plasma SN levels did not differ according to age and were not associated with comorbidities, left ventricular ejection fraction, heart failure medication, troponin, creatinine, or natriuretic peptide plasma levels. CONCLUSION: Plasma secretoneurin levels differed significantly in DCM vs. ICM, being higher in the former. Based on plasma SN levels, discrimination between DCM and ICM might be possible. Healthy individuals produce higher SN plasma levels than stable HFrEF patients.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dodulík, Jozef $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czechia
700    1_
$a Lazárová, Marie $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czechia
700    1_
$a Stejskal, David $u Institute of Laboratory Medicine, University Hospital Ostrava, Ostrava, Czechia $u Institute of Laboratory Medicine, University of Ostrava, Ostrava, Czechia
700    1_
$a Švagera, Zdeněk $u Institute of Laboratory Medicine, University Hospital Ostrava, Ostrava, Czechia $u Institute of Laboratory Medicine, University of Ostrava, Ostrava, Czechia
700    1_
$a Chobolová, Nela $u Institute of Laboratory Medicine, University Hospital Ostrava, Ostrava, Czechia
700    1_
$a Šulc, Patrik $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czechia
700    1_
$a Evin, Lukáš $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czechia $u Research Center for Internal and Cardiovascular Diseases Faculty of Medicine, University of Ostrava, Ostrava, Czechia $7 xx0327372
700    1_
$a Purová, Dana $u Social Health Institute, Palacky University Olomouc, Olomouc, Czechia
700    1_
$a Václavík, Jan $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czechia $u Research Center for Internal and Cardiovascular Diseases Faculty of Medicine, University of Ostrava, Ostrava, Czechia
773    0_
$w MED00198704 $t Frontiers in cardiovascular medicine $x 2297-055X $g Roč. 10 (20240108), s. 1297900
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38259301 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240405 $b ABA008
991    __
$a 20250108155135 $b ABA008
999    __
$a ok $b bmc $g 2076108 $s 1215816
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 10 $c - $d 1297900 $e 20240108 $i 2297-055X $m Frontiers in cardiovascular medicine $n Front Cardiovasc Med $x MED00198704
LZP    __
$a Pubmed-20240405

Najít záznam

Citační ukazatele

Možnosti archivace